MedTrace Logo

Electronic Hookah and Endothelial Cell Function

NCT04133376 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-03-12

No results posted yet for this study

Summary

Electronic nicotine delivery systems (ENDS) are a rapidly growing global epidemic among adolescents and young adults. Unlike other ENDS such as e-cigarettes, e-hookahs are used through traditional water-pipes, allowing the vapor-containing nicotine, propylene glycol, glycerin, and flavorings-to pass through a water-filled basin, potentially altering the vapor, before it is inhaled through the user's mouth. Contributing to e-hookahs popularity is the belief that the flavored smoke is detoxified as it passes through the water-filled basin, rendering e-hookah a safer tobacco alternative. However, an e-hookahs deliver flavored nicotine by creating a vapor of fine particles and volatile organic compounds that could induce vascular toxicity. While e-hookah vaping acutely reduces endothelial function, the specific role of nicotine and the mechanisms by which it may impairs endothelial function remain understudied. The objective of this project is to investigate the specific role of nicotine in mediating the acute effects of e-hookah vaping on endothelial dysfunction.

Conditions

  • Smoking
  • Endothelial Dysfunction

Interventions

OTHER

Electronic hookah vaping with nicotine

Participants will be invited to vape a 30-minute session of e-hookah containing nicotine

OTHER

Electronic hookah vaping without nicotine

Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine

Sponsors & Collaborators

Principal Investigators

  • Mary Rezk-Hanna, PhD · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-16
Primary Completion
2022-11-29
Completion
2023-05-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04133376 on ClinicalTrials.gov